Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
03/2005
03/17/2005CA2741575A1 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
03/17/2005CA2741412A1 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
03/17/2005CA2538169A1 Transition state analog inhibitors of ricin a-chain
03/17/2005CA2537765A1 Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas
03/17/2005CA2537290A1 Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
03/17/2005CA2536975A1 Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
03/17/2005CA2536967A1 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
03/17/2005CA2536512A1 Rage-related methods and compositions for treating glomerular injury
03/17/2005CA2536175A1 Pharmaceutical compositions and method of using levodopa and carbidopa
03/17/2005CA2536061A1 Polymeric systems for controlled drug therapy
03/17/2005CA2535889A1 Combination methods of treating cancer
03/17/2005CA2535780A1 Antibiotic product, use and formulation thereof
03/17/2005CA2535770A1 Method for detecting cancer cells and monitoring cancer therapy
03/17/2005CA2526398A1 Human monoclonal antibodies against bacillus anthracis protective antigen
03/16/2005EP1514559A1 Arylpiperazines having activity at the serotonin 1a receptor
03/16/2005EP1513806A1 New salts
03/16/2005EP1513800A1 N-benzoylureidocinnamate derivatives, method for production and use thereof
03/16/2005EP1513525A1 Use of mglur5 antagonists for the treatment of gerd
03/16/2005EP1115371B1 Oral care compositions
03/16/2005EP0907737B1 Il-6 mutein
03/16/2005EP0869966B1 Prodrugs of thrombin inhibitors
03/16/2005CN1596256A Methods for the purification of levofloxacin
03/16/2005CN1193028C Dual molecules containing peroxide derivative; synthesis and therapeutic applications thereof
03/16/2005CN1193025C Novel 1, 3-dihydro-2H-indol-2-one derivatives, their preparing method and pharmceutical composition containing the same
03/16/2005CN1192798C Vaccine
03/15/2005US6867182 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof
03/15/2005US6866843 Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
03/15/2005CA2334870C Polymorphic form of clopidogrel hydrogen sulphate
03/10/2005WO2005021777A2 Uses of spatial configuration to modulate protein function
03/10/2005WO2005020935A2 Method and composition of administering radioprotectants
03/10/2005WO2005020934A2 Fsh glycosylation mutant
03/10/2005WO2005020933A2 Nanoparticles for drug-delivery
03/10/2005WO2005020932A2 Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
03/10/2005WO2005020931A2 Systems and methods for treating hemorrhoids
03/10/2005WO2005020930A2 Improved syntheses of alitame
03/10/2005WO2005020928A2 Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
03/10/2005WO2005020927A2 Method of promoting graft survival with anti-tissue factor antibodies
03/10/2005WO2005020926A2 Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
03/10/2005WO2005020925A2 Method and apparatus for dosing solids
03/10/2005WO2005020924A2 A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
03/10/2005WO2005020923A2 Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
03/10/2005WO2005020922A2 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
03/10/2005WO2005020921A2 C-kit modulators and methods of use
03/10/2005WO2005020920A2 Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
03/10/2005WO2005020919A2 Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor
03/10/2005WO2005020918A2 Ultrasonic concentration of drug delivery capsules
03/10/2005WO2005020917A2 Ophthalmic compositions for treating ocular hypertension
03/10/2005WO2005020916A2 Myoblast treatment of diseased or weakened organs
03/10/2005WO2005020915A2 Silver dihydrogen citrate compositions comprising a second antimicrobial agent
03/10/2005WO2005020914A2 Pyridomorphinans, pyridazinomorphinans and use thereof
03/10/2005WO2005020913A2 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
03/10/2005WO2005020912A2 Delivery of immune response modifier compounds
03/10/2005WO2005020911A2 Benzo[1, 3]dioxole compounds, pharmaceutical compositions thereof, and processes of making and using the same
03/10/2005WO2005020910A2 Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
03/10/2005WO2005020909A2 Cellular depolarization and regulation of matrix metalloproteinases
03/10/2005WO2005020907A2 Ocular drug delivery device
03/10/2005WO2005020906A2 Intranasal opioid compositions
03/10/2005WO2005020905A2 Echogenic coatings with overcoat
03/10/2005WO2005020904A2 Oral neurotherapeutic cefazolin compositions
03/10/2005WO2005020903A2 Methods of improving the safety of zonisamide therapy
03/10/2005WO2005020902A2 Compositions and methods for treating and diagnosing irritable bowel syndrome
03/10/2005WO2005020901A2 Delivery of a therapeutic agent in a formulation for reduced toxicity
03/10/2005WO2005020900A2 Delivery of a therapeutic agent in a formulation for reduced toxicity
03/10/2005WO2005020896A2 N,n-dihalogenated amino acids and derivatives
03/10/2005WO2005020895A2 Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
03/10/2005WO2005020893A2 Therapeutic platelets and methods
03/10/2005WO2005020892A2 Pharmaceutical compositions and methods for metabolic modulation
03/10/2005WO2005020891A2 Monoclonal antibodies against ricin toxin and methods of making and using thereof
03/10/2005WO2005020890A2 Multiplexed molecular beacon assay for detection of pathogens
03/10/2005WO2005020888A2 Compositions and methods of treating and diagnosing hepatoma
03/10/2005WO2005020886A2 Identification and use of cofactor independent phosphoglycerate mutase as a drug target
03/10/2005WO2005020885A2 Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
03/10/2005WO2005020883A2 Methods for the production of ansamitocins
03/10/2005WO2005020882A2 Compound capable of binding s1p receptor and pharmaceutical use thereof
03/10/2005WO2005020880A2 Methods for the treatment of endometriosis
03/10/2005WO2005020879A2 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
03/10/2005WO2005020689A1 Anti-virus hydrophilic polymeric material
03/10/2005WO2005011583A3 Treatment of allergic rhinitis and asthma
03/10/2005WO2005011572A3 Combination of drugs for the treatment of neoplasms
03/10/2005WO2005002496A3 Method of obtaining taxosteroids and precursors thereof
03/10/2005WO2004112730A3 Method and compositions for treating tumors
03/10/2005WO2004112700A8 Methods and compositions for modulating amyloid precursor protein translation
03/10/2005WO2004110380A3 Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
03/10/2005WO2004110360A9 Proteoglycan degrading mutants for treatment of cns
03/10/2005WO2004108075A3 Self-warming or self-heating cosmetic and dermatological compositions and method of use
03/10/2005WO2004105690A3 Treatment of chronic pain associated with drug or radiation therapy
03/10/2005WO2004105689A3 Topical composition for the treatment of skin disorders and methods of using the same
03/10/2005WO2004105687A3 Antimicrobial quaternary ammonium organosilane coatings
03/10/2005WO2004103317A3 Transdermal buprenorphine dosage regimen for treatment of diarrhea
03/10/2005WO2004103285A3 Lactoferrin in the treatment of diabetes mellitus
03/10/2005WO2004103278A3 Acyl sulfonamides as inhibitors of hiv integrase
03/10/2005WO2004098497A3 Cd4+ human papillomavirus (hpv) epitopes
03/10/2005WO2004096128A3 Hiv integrase inhibitors
03/10/2005WO2004091497A3 Methods and compositions for increasing the anaerobic working capacity in tissues
03/10/2005WO2004089289A3 Treating or preventing hot flashes using prodrugs of gaba analogs
03/10/2005WO2004082627A3 ENZYME REPLACEMENT THERAPY WITH 17-β-HYDROXYSTEROID DEHYDROGENASE-TYPE 2
03/10/2005WO2004082613A3 2,4-diamino-5-[5’-substituted-benzyl] pyrimidines and 2,4-diamino-6-[5’-substituted-benzyl] quinazolines
03/10/2005WO2004082611A3 Poss and eposs containing cosmetics and personal care products
03/10/2005WO2004082601A3 Method of treating diabetes and diabetes-related disorders
03/10/2005WO2004071447B1 Substituted azole derivatives as therapeutic agents
1 ... 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 ... 295